T1	Participants 63 99	postoperative rectal cancer patients
T2	Participants 319 355	postoperative rectal cancer patients
T3	Participants 435 492	Four hundred patients with stage II and III rectal cancer
T4	Participants 626 672	patients were randomly divided into two groups
T5	Participants 675 711	wo hundred and twenty-eight patients
T6	Participants 786 798	172 patients
T7	Participants 996 1035	genotype of CCND1 A870G in the patients
T8	Participants 1336 1348	136 patients
T9	Participants 1526 1553	patients without severe AEs
T10	Participants 1592 1632	severe diarrhea occurred in 109 patients
T11	Participants 1692 1736	15.6%, 47.7% and 36.7% among these patients,
T12	Participants 1795 1828	patients without severe diarrhea.
T13	Participants 1928 1953	patients with AA genotype
T14	Participants 2014 2032	GG or GA genotypes
T15	Participants 2092 2117	patients with AA genotype
T16	Participants 2228 2246	GG or GA genotypes
T17	Participants 2259 2272	Cap-CRT group
T18	Participants 2073 2090	Cap-Oxa-CRT group
T19	Participants 2446 2499	postoperative stage II and III rectal cancer patients
